Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NPM1
REST API REST API
Homo sapiens
NPM1 is differentially expressed in 297 experiments: 148 organism parts: liver, ovary, ... (146 more);, 252 disease states: normal, glioblastoma, ... (250 more);, 98 cell types 420 cell lines 39 compound treatments and 82 other conditions.
Synonyms NPM, B23
Orthologs npm1b (Danio rerio)   Q6LEK2_CHICK (Gallus gallus)   npm1 (Danio rerio)   F1M6T8_RAT (Rattus norvegicus)   npm1 (Xenopus laevis)   XM_861566.1 (Canis familiaris)   LOC479292 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein localization, protein binding, DNA repair, cytoskeleton, cytoplasm, histone binding, ribosomal small subunit binding, negative regulation of cell proliferation, ribonucleoprotein complex, intracellular protein transport, nucleic acid binding, response to stress, anti-apoptosis, protein oligomerization, ribosome assembly, centrosome, centrosome cycle, transcription coactivator activity, nucleus, protein heterodimerization activity, spindle pole centrosome, unfolded protein binding, protein homodimerization activity, positive regulation of NF-kappaB transcription factor activity, nucleoplasm, nucleocytoplasmic transport, signal transduction, RNA binding, nucleosome assembly, nucleolus, CenH3-containing nucleosome assembly at centromere, cell aging, ribosomal large subunit binding, Tat protein binding, interspecies interaction between organisms, NF-kappaB binding, negative regulation of centrosome duplication, regulation of endoribonuclease activity, regulation of endodeoxyribonuclease activity
InterPro Term Nucleoplasmin
UniProt Accession Q9NX34, Q9BTI9, P06748, Q9BYG9, E5RGW4, E5RI98
Gene-Disease Assocation LEUKEMIA, ACUTE MYELOID; AML
Search EB-eye ENSG00000181163
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-MEXP-433, E-GEOD-3526, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (34 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
MCF-10A
2
E-TABM-420, E-GEOD-14990
WI38
2
E-MTAB-37, E-MTAB-62
BT474
1
2
E-MEXP-440, E-MTAB-62, E-MTAB-37
ITV
1
E-GEOD-2487
414 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-3920, E-MEXP-750, E-GEOD-4219, E-GEOD-13909, ... (46 experiments)

Factor Value U/D Experiments
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
CD34+
2
E-AFMX-5, E-TABM-145
CD4+ T cell
2
E-GEOD-16190, E-AFMX-5
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
fibroblast
2
E-GEOD-3920, E-GEOD-3204
endothelial cell
1
2
E-GEOD-96, E-GEOD-3920, E-GEOD-19240
92 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-TABM-15, ... (64 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-62, E-GEOD-3726, E-MTAB-57
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-MEXP-231
neuroblastoma
3
E-MTAB-37, E-GEOD-1825, E-MTAB-62
prostate carcinoma
1
3
E-GEOD-96, E-MEXP-1327, E-MTAB-62, E-TABM-26
malignant melanoma
2
E-MTAB-62, E-GEOD-3189
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
246 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3720
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
5-aza-2'-deoxycytidine
2
1
E-GEOD-5230
keratinocyte growth factor
1
E-GEOD-7216
NaOH
1
E-MEXP-2590
phoshate buffered saline
1
E-GEOD-3720
33 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
31
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1638, E-GEOD-20033, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-19665, E-GEOD-1751

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1437, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-GEOD-12773, ... (12 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-276, E-GEOD-20194, E-GEOD-16716, E-GEOD-2748

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-176, E-MEXP-2069, E-GEOD-19519, ... (23 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22152, E-GEOD-22309, E-GEOD-21750, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Vehicle
studied in E-GEOD-5258

Processing time: 0.3 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM